ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 2868

Distinct Plasma Cytokine Profiles Across Rheumatic Diseases Reveal an RA-Specific Interstitial Lung Disease Signature

Liva Pfuhler1, Mazen Zenati2, Caleb Watson2, Samuel Chiang3, Cristina Cobb3, Dana Ascherman4 and Daniella Schwartz4

Affiliations: 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3Cincinnati Children's Hospital, Cincinnati, 4University of Pittsburgh, Pittsburgh

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: cytokines, interferon, interstitial lung disease, Myositis, rheumatoid arthritis

Session Information

Date: Tuesday, November 10, 2026

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: Focus on Antigenic-based and Autoimmune Disease (2863-2868)

Session Type: Abstract Session

Session Time: 2:15PM-2:30PM

Background/Purpose:

Systemic autoimmune rheumatic diseases (SARDs) cause significant morbidity and mortality through diverse mechanisms. Major implicated drivers include interferon (IFN), T cell, inflammasome/IL-6, and TNF-α signaling. Interstitial lung disease (ILD) is a major comorbidity of SARDs, including rheumatoid arthritis (RA), myositis, and systemic sclerosis (SSc). However, plasma cytokine profiles have not been systematically compared across SARD-ILD states. We hypothesized that cytokine profiles would differ across SARDs, associate with ILD status in a SARD-specific manner, and reveal distinct interferon-associated signatures among myositis subtypes.

Methods:

Plasma was collected 2011-2025 from 125 patients. Patients carried diagnoses of RA (n=30, 15 ILD), SSc (n=35,19), MDA5-myositis (n=19, 9), Jo-1-myositis (n=31, 16), and healthy controls (HC, n=10). ILD status was assessed by chart review. Cytokines were selected from mRNA sequencing data implicating IFN signaling in ILD. Plasma CXCL9, CXCL10, IL-18, IL-2Rα, and TNF-α were measured by Ella automated immunoassay (Bio-Techne). Log-transformed cytokine levels were analyzed using rank-based regression models incorporating disease, ILD status, and disease × ILD status interaction terms, with FDR multiple comparison correction. A separate FDR-corrected model compared each disease to HC. Per-patient CXCL9/CXCL10 ratios were compared between myositis subtypes and by ILD status.

Results:

Disease × ILD interactions were seen for CXCL9, CXCL10, IL-2Rα, and TNF-α (Fig 1a). Specifically in RA, ILD was associated with significantly higher levels of these cytokines (Fig 1b). Within other SARDs, no comparable ILD-associated elevations were observed, indicating this is specific to RA. Additionally, TNF-α was lower in MDA5 patients with ILD than in those without (Fig 1b).  

Notably, CXCL9 and CXCL10 were elevated in non-RA SARDs regardless of ILD status, reflecting SARD- rather than ILD-driven elevation. Among SARDs, median CXCL9 was highest in Jo-1 and CXCL10 in MDA5 myositis, respectively. Correspondingly, in Jo-1, CXCL9/10 ratios showed a ~3.2-fold increase in CXCL9 over CXCL10, while in MDA5, the levels of CXCL9 and CXCL10 were approximately balanced, both independent of ILD status (Fig 2). Of all disease groups, IL-18 was elevated relative to HC in only MDA5 (p_adj=0.037).

Conclusion:

Plasma cytokine profiles differed across SARDs, and ILD-associated elevation was specific to RA. Jo-1 and MDA5 exhibited contrasting CXCL9/CXCL10 ratios, consistent with previously reported type II vs. type I interferon pathway induction, while elevated IL-18 in MDA5 suggesting macrophage activation. These findings reveal disease-specific inflammatory signatures and identify an RA-specific association between ILD status and cytokine levels that may provide insight into disease biology with potential diagnostic implications.

Supporting image 1Figure 1. Plasma cytokines by disease and ILD status. Drop-in-dispersion p per model term, FDR-adjusted (A). Cytokine by disease and ILD status, ILD effects obtained by refitting the model with each disease as reference, FDR-adjusted (B). *p<0.05, **p<0.01, ***p<0.001

Supporting image 2Figure 2. Per-patient log10(CXCL9/CXCL10), Jo-1 (n=31) and MDA5 (n=19); dash=balanced expression, positive=CXCL9 dominance, negative=CXCL10 dominance (p<0.001; Cliff's δ=0.78).


Disclosures: L. Pfuhler: None; M. Zenati: None; C. Watson: None; S. Chiang: None; C. Cobb: None; D. Ascherman: None; D. Schwartz: Electra, 12,, Eli Lilly, 12,, Sobi, 12,, 12, .

To cite this abstract in AMA style:

Pfuhler L, Zenati M, Watson C, Chiang S, Cobb C, Ascherman D, Schwartz D. Distinct Plasma Cytokine Profiles Across Rheumatic Diseases Reveal an RA-Specific Interstitial Lung Disease Signature [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/distinct-plasma-cytokine-profiles-across-rheumatic-diseases-reveal-an-ra-specific-interstitial-lung-disease-signature/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-plasma-cytokine-profiles-across-rheumatic-diseases-reveal-an-ra-specific-interstitial-lung-disease-signature/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology